[Market Focus] SillaJen Soars on Clinical Trial Protocol Amendment Approval

As of 9:20 a.m. on April 22, shares of SillaJen were trading at 3,020 won on the KOSDAQ market, up 23.77% from the previous day's closing price. This appears to be due to news of the approval for a change in clinical trial plans announced the previous day.

On April 21, SillaJen announced in a regulatory filing that its investigational drug BAL0891, being developed as a treatment for acute myeloid leukemia, had received approval from the U.S. Food and Drug Administration (FDA) for a change in its clinical trial protocol.

This Phase 1 clinical trial aims to evaluate the safety and tolerability of BAL0891 through dose escalation and expansion studies in patients with advanced solid tumors or relapsed/refractory acute myeloid leukemia. The trial includes dose escalation sub-studies assessing intravenous BAL0891 monotherapy, as well as combination therapies with carboplatin or paclitaxel.

On the same day, SillaJen also announced that it had decided to acquire substance and biomarker patent rights for BAL0891 from the Dutch biotechnology company Crossfire Oncology Holding B.V. The contract amount is 2 million Swiss francs (approximately 3.5 billion won).

This content was produced with the assistance of AI translation services.